Discoveries

FORUM REVIEW ARTICLE

Hydrogen Peroxide Sensing and Signaling by Protein Kinases in the Cardiovascular System

Joseph R. Burgoyne,[1] Shin-ichi Oka,[2] Niloofar Ale-Agha,[3] and Philip Eaton[1]

Abstract

Significance: Oxidants were once principally considered perpetrators of injury and disease. However, this has become an antiquated view, with cumulative evidence showing that the oxidant hydrogen peroxide serves as a signaling molecule. Hydrogen peroxide carries vital information about the redox state of the cell and is crucial for homeostatic regulation during health and adaptation to stress. *Recent Advances:* In this review, we examine the contemporary concepts for how hydrogen peroxide is sensed and transduced into a biological response by introducing post-translational oxidative modifications on select proteins. Oxidant sensing and signaling by kinases are of particular importance as they integrate oxidant signals into phospho-regulated pathways. We focus on CAMKII, PKA, and PKG, kinases whose redox regulation has notable impact on cardiovascular function. *Critical Issues:* In addition, we examine the mechanism for regulating intracellular hydrogen peroxide, considering the net concentrations that may accumulate. The effects of endogenously generated oxidants are often modeled by applying exogenous hydrogen peroxide to cells or tissues. Here we consider whether model systems exposed to exogenous hydrogen peroxide have relevance to systems where the oxidant is generated endogenously, and if so, what concentration can be justified in terms of relevance to health and disease. *Future Directions:* Improving our understanding of hydrogen peroxide signaling and the sensor proteins that it can modify will help us develop new strategies to regulate intracellular signaling to prevent disease. *Antioxid. Redox Signal.* 18, 1042–1052.

Hydrogen Peroxide—Roles in Health and Disease

HYDROGEN PEROXIDE (H_2O_2), like other oxidants, has historically been considered a damaging entity that causatively mediates cardiovascular disease. The rational is that H_2O_2 oxidizes various biomolecules, resulting in their loss of function and causing damage that ultimately compromises cellular function. For example, H_2O_2 has been shown to injure or even stimulate cell death when administered to numerous different model systems (21). However, oxidant-induced injury studies are often self-fulfilling. As H_2O_2 is anticipated to be damaging, the concentration used in experimental models is often without question as long as it generates the anticipated injury. This essentially means the starting point for implementing a model of oxidant stress is to add sufficient oxidant to induce injury, without consideration that there may be oxidant-induced changes in cell function well before the damaging concentrations are reached. The use of inappropriately high concentrations of H_2O_2 has perhaps been widely accepted because they yield data consistent with the view that oxidants are primarily harmful. As a consequence, numerous studies show H_2O_2 causing injury, and this is mitigated by co-treatment with various antioxidants, which are envisaged to scavenge the oxidant to prevent it oxidatively modifying (*i.e.*, damaging) key components within the cell. However, amongst the vast numbers of studies reporting oxidants as damaging, there are others that show they can initiate cytoprotection. Indeed, a role for H_2O_2 as a nondamaging entity that is important for cellular homeostasis or stress adaptation has gained increasing attention.

Although many pre-clinical studies report antioxidant protection against disease in models that promote oxidative stress, it should be remembered that these protective effects have not been observed in large-scale human clinical trials. In fact, such trials have not only failed to protect against disease, but in many cases these antioxidant supplements (especially when vitamin E or beta carotene have been used) have been detrimental, including

[1]Department of Cardiology, King's College London, The Rayne Institute, St. Thomas' Hospital, London, United Kingdom.
[2]Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey.
[3]Department of Molecular Cell & Aging Research, IUF at the University of Düsseldorf gGmbH, Düsseldorf, Germany.

in the cardiovascular system (7). Such observations, along with cumulative new evidence that H$_2$O$_2$ plays important regulatory roles, have further added to the contemporary view that these oxidants are crucial signaling molecules. Indeed, as antioxidants are anticipated to prevent oxidant sensing and signaling, this could potentially explain the harm they can cause, perhaps by preventing an appropriate homeostatic or adaptive response.

Here we consider the concentrations of H$_2$O$_2$ that are produced in biological systems, assessing whether there is a disconnect between those levels and what is normally added exogenously in experimental model systems to observe a biological response. Many proteins are now known to sense H$_2$O$_2$ and alter their function as a result, providing a mechanism by which an oxidant signal is transduced into a biological response. We also discuss the molecular basis of H$_2$O$_2$ sensing by these proteins, specifically focusing on kinases that have been shown to be regulated by post-translational oxidative modifications. These kinases, CAMKII, PKA, and PKG, are not only well known as important regulators of cardiovascular function, but there is significant evidence showing their redox regulation. Modulation of kinases in this way is significant as this allows direct integration of changes in cellular redox status with phospho-regulatory pathways. In addition to the direct modulation of CAMKII, PKA, and PKG by oxidants, there are several other kinases that can be indirectly modulated via protein oxidation of upstream targets. This includes apoptosis signal-regulating kinase-1 (ASK-1), which is kept inactive through an interaction with reduced thioredoxin (Trx). This interaction is disrupted by reactive oxygen species that oxidize Trx, preventing it from binding ASK-1. This leads to the activation of ASK-1 and subsequent stimulation of ASK-1 dependent apoptosis (49).

H$_2$O$_2$—How Is it Produced?

The reduced oxygen species superoxide is constantly generated in cells as a by-product of metabolism or by specialist

FIG. 1. Cellular sources of superoxide and hydrogen peroxide. Changes in H$_2$O$_2$ formation play an important role in physiological signaling. However dysregulation can lead to dysfunction and disease progression.

oxidase enzymes (Fig. 1). Superoxide is readily converted to the more stable form H$_2$O$_2$ following reduction by superoxide dismutase or spontaneous decomposition (37). Once formed, H$_2$O$_2$ acts as a physiological second messenger signaling molecule by selectively oxidizing target or sensor proteins, as discussed below. In addition to oxidases, the mitochondrial transport chain also generates superoxide through the leak of electrons that combine with molecular oxygen to yield superoxide. Therefore, the metabolic state of the cell alters the rate at which electrons leak from their transport chains, changing the amount of superoxide and H$_2$O$_2$ generated. Out of numerous oxidase enzymes, the NADPH oxidase (NOX) family of proteins are the only with a primary role in generating superoxide and H$_2$O$_2$ (14). Superoxide is also enzymatically generated as a by-product by xanthine oxidase, uncoupled nitric oxide synthases, urate oxidase, aldehyde oxidase, D-amino oxidases (such as monoamine oxidase, indoleamine 2,3-dioxygenase), as well as by any peroxidase that can reduce molecular oxygen to superoxide (18).

H$_2$O$_2$—How Much Is Produced and Accumulates in Cells and Tissues?

The net cellular H$_2$O$_2$ concentration depends on the rate of increase (influenced by influx and the rate of endogenous synthesis) against consumption by conversion to water or other reactive oxidant species (ROS), as well the efflux rate. Measurement of H$_2$O$_2$ in samples has revealed that normal human plasma typically contains 1–8 μM H$_2$O$_2$ (with an average of $\sim 3 \mu M$) (35, 36), although 35 μM has also been observed. Higher concentrations have been observed in activated macrophages, which can generate up to 6×10^{-14} mol H$_2$O$_2$/h/cell, generating a local concentration of 10–1002 μM (19). In addition, stimulated neutrophils were shown to release H$_2$O$_2$ that accumulated at 1–12 μM in the extracellular medium (57, 60). Elevations in H$_2$O$_2$ were detected during disease, including ischemia and reperfusion where an extracellular H$_2$O$_2$ concentration of 100 μM was observed in the brain (30). Individual cells lining the gut and urinary tract are routinely exposed to 100 μM H$_2$O$_2$ (18), while respiratory lining cells experience 0.1–1μM H$_2$O$_2$, but can be elevated 20-fold in subjects with inflammatory lung disease (34, 59). Elevations in H$_2$O$_2$ have also been reported in end-stage kidney disease (13 μM) (27), hypertension (7 μM) (35), and ischemia and reperfusion (160 μM) (30). In addition, patients with respiratory lung neutrophilia have μM levels of H$_2$O$_2$ in their breath condensates (3). In contrast to extracellular measurements, direct measurement of intercellular H$_2$O$_2$ is markedly more challenging due to rapid reactivity of this oxidant species (short lived), although some such studies suggest mM H$_2$O$_2$ can occur (57). An important consideration is that the subcellular concentration of H$_2$O$_2$ can vary hugely and be much higher in an individual cell or cellular compartment as compared to a cell-wide average concentration.

H$_2$O$_2$—Exogenous Treatment in Model Systems

Oxidative stress is routinely studied by exposing model systems to exogenous H$_2$O$_2$. In many studies an acute (5–10 min) oxidative interventions is utilized, with ~ 50–500 μM H$_2$O$_2$ being required to induce measureable protein oxidation or functional effects reliably. The relevance of this concentration range of H$_2$O$_2$ to health or to disease is hotly

debated, albeit we would contend that the studies discussed above justify such levels, at least pathophysiologically. It should be remembered that the exogenous H_2O_2 concentration will not be the same as in the intracellular environment due to impedance by the cell membrane (2). Although such concentrations are considered highly toxic by some researchers, in our isolated rat heart studies there was no detrimental impact when they were exposed acutely to 100 μM H_2O_2. Although cardiac contractility was quickly reduced to ~85% of basal left ventricular developed pressure and the coronary vessels vasodilated, the preparation remained stable thereafter (8, 12). Similarly, isolated ventricular myocytes tolerate similar levels of oxidants, including H_2O_2, without acute cell death. It is also notable that many high profile studies exposed cells and tissues to 100 μM H_2O_2 and above. Biteau *et al.* used 500 μM H_2O_2 during the discovery of sulphiredoxin (5). Woo *et al.* also demonstrated the reversibility of peroxiredoxin oxidation, using H_2O_2 at 100–500 μM (64). Sestrin-mediated repair of hyperoxidized peroxiredoxin was demonstrated in cells exposed to 100–500 μM H_2O_2 for 6 hours (11), and redox control of forkhead proteins illustrated using 100–1000 μM H_2O_2 (42). The H_2O_2 concentration in the cell induced by TNF reaches levels proportionally similar to the concentration induced by exogenous addition of 1–3 mM H_2O_2, although it can be fatal after a certain threshold (32). In addition to the concentration, we should be aware of the total amount of H_2O_2 to which cells are exposed. Even though an identical concentration of H_2O_2 is used, increasing the volume applied to the same amount of cells could result in increased oxidative damage because scavenging H_2O_2 requires a certain amount of electrons, which have a limited availability within the intracellular environment.

As highlighted above, membranes limit H_2O_2 entry into cells such that the intracellular concentration is less than that applied, perhaps 1/7th (2). On entry to the cell, the H_2O_2 encounters a buffered reducing environment, as well as several antioxidant enzymes that further lower the concentration. For example, cells including cardiac myocytes are replete in catalase which decomposes H_2O_2 with a Km >1 M (43). As this enzyme has evolved with such a high half constant for decomposing H_2O_2, it may suggest extremely high H_2O_2 levels occur within some intracellular locations. Such high H_2O_2 levels may be anticipated near the site of synthesis or at specific subcellular locations with an oxidizing redox potential such as peroxisomes, the endoplasmic reticulum, or outside the cell. The H_2O_2 buffering system of the cell also comprises of other peroxidases other than catalase, which includes glutathione peroxidase. Glutathionine peroxidases are found in most mammalian cells and use glutathione as an electron donor to reduce H_2O_2 to water. Mammalian cells also have many highly abundant isoforms of peroxiredoxin that decompose H_2O_2, and are considered the primary controllers of basal H_2O_2 levels, crucial to the control of redox signaling.

Peroxiredoxins have a K_m for their substrate H_2O_2 in the 10–20 μM range and have been suggested to act as gate keepers of oxidant signaling, as higher concentrations of H_2O_2 induce hyperoxidation of their catalytic cysteine to sulfinic acid which prevents H_2O_2 decomposition. This hyperoxidation event allows cellular peroxide to rise and so oxidize proteins that would not normally with active peroxiredoxin present, known as the 'floodgate' hypothesis (65). This 'gate' is subsequently closed by the reactivation of the peroxiredoxin, which is achieved by an ATP-dependent enzyme

called sulfiredoxin (5). This repair of sulfinated peroxiredoxin is supported by structural studies of this enzyme in a complex with sulfiredoxin (31). For such a repair mechanism to have evolved is logically consistent with peroxiredoxin being a natural, instead of an artefactual, occurrence. With this in mind, it is intriguing that peroxiredoxin hyperoxidation is not observed until cells or tissues are exposed to ~100 μM H_2O_2 (39, 52). This suggests such H_2O_2 concentrations are biologically relevant. Although exogenous H_2O_2 of ~100 μM and above is generally required for peroxiredoxin hyperoxidation, the intracellular concentration remains an important question. 2.4 μM Prx I efficiently reduced 100 μM H_2O_2 *in vitro* (66), but when H_2O_2 was cumulatively increased to 200, 500, or 1000 μM, this progressively inhibited peroxidase activity as a result of hyperoxidation. The transition point at which the peroxidatic thiol hyperoxidized was when H_2O_2 was 10-fold the peroxiredoxins K_m for substrate (i.e., at 200 μM). At this point, H_2O_2 was in a 40-fold molar excess over the peroxidase, suggesting the peroxidase hyperoxidation in cells may require a similar excess of H_2O_2 over peroxiredoxin. The molar concentration of peroxiredoxin is therefore an important question. Peroxiredoxins are highly abundant, constituting 0.1–0.8% of the total protein in some cells, with >10^6 copies per cell. Heart cells are replete with peroxiredoxins; perhaps present at ~40 μM (53). On this basis, we could expect that the concentration of H_2O_2 substrate of this enzyme (*i.e.*, H_2O_2) occasionally to be of the same order, or perhaps an order of magnitude or more above. As peroxiredoxins decompose H_2O_2 with a rate constant of up to 10^7 M^{-1} s^{-1} (46), this suggests the cellular concentration of oxidant is somewhat above that of enzyme that efficiently metabolizes it. Overall, these considerations may suggest that treatment of cardiac cells and tissues with 100–500 μM H_2O_2 is justified in terms of physiological significance.

H_2O_2 Sensing by Cysteine Thiols

A primary way that H_2O_2 is sensed and transduced into a biological response involves the oxidation of protein thiols (PSH) that have a low pKa (Fig. 3). These post-translational oxidative modifications can control the activity of target proteins in much the same way as related control mechanisms such as phosphorylation. Low pKa protein thiols exist substantially in the deprotonated thiolate anion (PS⁻) state at physiological pH. This ionized state profoundly increases the rate of oxidation by H_2O_2 and also provides a basis for selective H_2O_2 signaling. If H_2O_2 indiscriminately oxidized any protein thiol with which it came in contact, this would result in uncontrolled modifications and would be inconsistent with this oxidant serving as a messenger molecule that conveys information. Further selectivity may also be achieved by co-localization of the source of H_2O_2 with the redox-regulated target protein, as has been shown to occur in the regulation of S-nitrosylation by nitric oxide formation (25).

Figure 2 shows how reactive protein thiols can be oxidized by H_2O_2 to yield the sulfenic acid derivative (PSOH), which is generally unstable and can further oxidize stepwise to the sulfinic acid (PSO$_2$H) and then to the sulfonic acid (PSO$_3$H) form. Sulfenic acids can also be redox recycled, normally by forming a disulfide intermediate before conversion back to a thiol, commonly by glutathione- or thioredoxin-dependent reducing systems. Thiol over-oxidation to sulfinic or sulfonic acids were thought irreversible modifications, but at least in

FIG. 2. **Oxidative post-translational modifications of the amino acids cysteine and methionine.**

the case of the sulfinated form of the 2-Cys peroxiredoxin family of enzymes, this can be reduced back to the catalytically active thiol, as discussed above (5). Budanov *et al.* have also shown that a sulfinic acid form of peroxiredoxin 1 can be reduced by p53-regulated sestrin 2, although subsequent studies have questioned this finding (63). Other proteins form the sulfinated state, including DJ1, glyceraldehyde phosphate dehydrogenase, and protein tyrosine phosphatase 1B (PTP1B) (39). PTP1B can also form a relatively stable sulfenyl-amide, where a sulfenic acid reacts further with the amide nitrogen within the backbone of this protein (50), which being reversible may serve to prevent cysteine over-oxidation. Disulfides commonly form when proteins sulfenates encounter a thiol (Fig. 3), and can serve as a general mechanism to protect from over-oxidation. This is because disulfide-oxidized proteins can return to their basal reduced state when a cell recovers from an oxidant stress, whereas in most cases a protein sulfinate or sulfonate would require *de novo* synthesis. The type of disulfide formed depends on the thiol with which sulfenates react. The thiol can come from a small thiol-containing molecule, generating a disulfide adduct in a process known as S-thiolation. The small thiol is most commonly glutathione due to its abundance, resulting in S-glutathiolation of the target. In proteins with an appropriate structure, a sulfenate may be proximal to a neighboring (known as vicinal) thiol, giving rise to interprotein or intraprotein disulfides (9, 22). Protein thiols are also post-translationally modified and potentially regulated by many other molecules, including elec-

trophilic lipids, foodstuffs, and drugs or their metabolites (15,16). Examples include the lipid 15-PGJ2 (15-deoxy-Δ12,14-prostaglandin J2), which can modify a cysteine thiol on soluble epoxide hydrolase, leading to attenuation of its activity. This is through a Michael addition reaction whereby the α,β-unsaturated carbonyl group extracts electrons from the adjacent alkene, making this bond thiol reactive. An example of drugs that target cysteine thiols includes a group of ribosomal S6 kinase inhibitors (including hypothemycin) that adduct through a Michael addition reaction and could be potentially used in the treatment of cancer (68). Although cysteine thiols contribute to a large extent to the regulation of protein function by H_2O_2, the amino acid methionine can also plays an important role by undergoing oxidation. Methionine can be oxidized in the presence of H_2O_2 to form a methionine sulfoxide ($PSOCH_3$), which can be catalytically reduced by methionine sulfoxidases or further oxidized to an irreversible methionine sulfone (PSO_2CH_3). The oxidation of methionine by H_2O_2 is particularly pertinent to the catalytic regulation of CAMKII, as described below.

In the molecular mechanism of H_2O_2 sensing discussed above, the scheme presented involves the direct reaction of the oxidant with a low pKa target thiol. Despite target proteins such as PTP1B having quite a low pKa (~6.8), it has been questioned whether direct oxidation by H_2O_2 is likely to occur in cells (62). This is because of the high abundance of peroxidase enzymes with a lower pKa (~5.5) and other structural features that allow reaction with H_2O_2 at a much faster rate.

FIG. 3. Reversibility of post-translational oxidative modifications found on cysteine and methionine residues. The glutathiolation of cysteine residues can be reversed by glutaredoxin (Grx), whereas disulfides tend to be reduced by thioredoxin (Trx). The oxidized sulfoxide form of methionine can be reduced by methionine sulfoxide reductase (MsrA).

However, it is clear that enzymes such as PTP1B are indeed oxidized in systems under oxidative stress. Such oxidations may occur as secondary to inactivation of the 2-Cys peroxiredoxin enzymes, as in the floodgate hypothesis outlined above. However, cells are generally replete in other antioxidant enzymes, including the glutathione-dependent 1-Cys peroxiredoxins and thioredoxin. One potential mechanism involves oxidants first reacting with proteins with highly reactive thiols (*e.g.*, peroxiredoxins or thioredoxin), oxidizing them to a sulfenate or a disulfide, which then reacts with the target such as PTP1B. In this scenario, the oxidant sensing and resulting transduction to another type of signal (in the case of PTP1B this would be phosphate inhibition) are achieved by separate proteins, in which the target is passed the 'oxidant signal' by the sensor.

Kinases That Are Redox Regulated by H_2O_2

Ca^{2+}/calmodulin-dependent kinase II

Ca^{2+}/calmodulin-dependent kinase II (CaMKII) exists as four isoforms (α, β, δ, γ) with δ being the most abundant in heart (54). This serine-threonine kinase phosphorylates many of the same targets as PKA. CaMKII contributes to the control of excitation–contraction coupling by regulating the activity of several Ca^{2+}-handling proteins, but is also a key controller of apoptosis and gene transcription.

Figure 4 shows the CaMKII holoenzyme consisting of monomeric units that comprise a catalytic N-terminal domain, a C-terminal association domain, and a central regulatory domain. The kinase holoenzyme assembles by monomers interacting through their association domains (28, 54). Figure 4 also shows that each holoenzyme is comprised of either dodecameric or tetradecameric monomer subunits which provide a large number of catalytic domains for in-

teraction with substrates. The CaMKII holoenzyme structure provides a basis for a graded or proportional response to Ca^{2+}. Ca^{2+}, the classical activator of CaMKII, enables catalytic activity via the formation of a Ca^{2+}/calmodulin complex that binds to and stimulates the kinase. Persistent Ca^{2+}-dependent activation leads to inter-subunit autophosphorylation at Thr-287 within the autoinhibitory domain, preventing re-association with the catalytic domain and sustained kinase activity even when Ca^{2+} returns to basal levels.

CaMKII is activated by oxidative stress, including in the heart, for example during apoptosis (69). Activation during oxidative stress led to the hypothesis that the kinase may be susceptible to direct oxidative activation, which was indeed the case. Ca^{2+}/CaM-activated CaMKII remained active even after Ca^{2+} was removed if H_2O_2 was present. Pre-activation by Ca^{2+}/CaM is required for H_2O_2-induced kinase activation, the targets of oxidation being inaccessible otherwise. The oxidation of two methionine residues underlies the oxidant-mediated activation of CaMKII; a Met282Val mutant being completely resistant to oxidative activation. A Met281Val on the other hand is only partially resistant to oxidative activation. Both 'redox-dead' mutants could be activated like wild-type when stimulated by autophosphorylation, whereas a Cys290Val mutant could be fully activated by oxidants like wild-type. A role for cysteine oxidation in CaMKII activation was ruled out, as iodacetic acid (which alkylates thiols) did not prevent H_2O_2-induced kinase activation. An antibody that selectivity recognizes the dual oxidized M281/282 form of CaMKII was used to show that AngII treatment promoted kinase oxidation in wild-type heart, whereas this did not occur in p47 NOX null mice. AngII-induced oxidative activation of CaMKII mice induced apoptosis in wild-type, but not p47 NOX null, mice. Similarly CaMKII transgenic mice expressing an inhibitory 'AC3-I' peptide were resistant to AngII-induced

FIG. 4. Structure of CAMKII, showing classical (autophosphorylation) and oxidative (methionine oxidation) modes of activation. For both forms of activation, Ca^{2+}/calmodulin must bind to the regulatory subunit first to expose the modifiable residues.

apoptosis (45). Further support for this oxidative activation of CaMKII mediating injury comes from studies replacing wild-type CaMKII with the Met281/282Val form that is resistant to apoptosis and hypertrophy.

Sulfoxidized methionine residues may be reversed back to the reduced state by methionine sulfoxide reductase A (MsrA), as shown in Figure 3. Mice lacking MsrA have increased sensitivity to AngII-induced CaMKII oxidation and apoptosis in heart tissue. Furthermore, MsrA null mice are sensitized to CaMKII oxidation, as well as apoptosis during myocardial infarction. These data strongly support a role for oxidative activation of CaMKII being causatively harmful. Oxidant-activated CaMKII potentially activates the L-type Ca^{2+} channel (55), with H_2O_2 increasing Ca^{2+} influx by this route. Depleting SR Ca^{2+} stores with caffeine or thapsigargin prevented oxidant-induced L-type Ca^{2+} channel activation, suggesting intracellular store of Ca^{2+} are also important (56). The cardiotoxic effects of aldosterone are significantly medi-

ated by oxidative activation of CaMKII (23). Hearts and isolated neonatal myocytes exposed to aldosterone had elevated ROS levels, and CaMKII methionine sulfoxidation was observed on immunoblots. Overexpression of MsrA reduced the detrimental effects of aldosterone. Aldosterone increased the expression of matrix metalloproteinase 9, a known mediator of the cardiac rupture phenotype, *in vivo* in mice,(26) and this was dependent on CaMKII oxidation, as it was absent in mice overexpressing AC3-I. This highlights the potential benefit and rationale for using mineralocorticoid receptor antagonist drugs to reduce the risk of mortality after myocardial infarction. The proposed mechanisms for classical and oxidative activation of CaMKII are shown in Figure 4.

cAMP-dependent protein kinase

Cyclic adenosine 3′,5′-monophosphate (cAMP)-dependent protein kinase is also commonly known as protein kinase A

FIG. 5. Classical cAMP and oxidative disulfide mechanism for activating PKAI. The binding of cAMP to the regulatory subunit of PKA causes dissociation of this subunit from the catalytic. The disassociation of these two subunits exposes the active site of the catalytic domain, allowing it to phosphorylate its substrates. Oxidative activation of PKARI involves the formation of two intermolecular disulfides, which enhance the affinity of PKARI for its binding partners the AKAPs. This brings PKA into close proximity with its substrates, which enhances their phosphorylation.

(PKA). PKA is classically activated by elevations in cAMP (Fig. 5) which is synthesized in response to sympathetic nerve stimulation that releases adrenaline or noradrenaline into the circulatory system (4). These hormones bind to β-adrenergic receptors to stimulate adenylate cyclase, via the stimulatory G-protein coupled signaling pathway, which converts adenosine-5'-triphosphate (ATP) to cAMP. This mechanism of β-adrenergic stimulation is a principal component of the physiological 'flight or fight' response, enhancing the body's ability to perform exercise. Enhanced physical activity requires increased myocardial contractility, elevating cardiac output to potentiate the supply of blood providing the oxygen and nutrients required for energy generation. cAMP binds to the regulatory subunits of this tetrameric kinase complex which dissociates them from the catalytic, resulting in substrate phosphorylation (33).

PKA is a major regulator of cardiac excitation–contraction coupling, enhancing Ca^{2+} influx into the cell by phosphorylating and activating the L-type Ca^{2+} channel. This Ca^{2+} stimulates the RyR, resulting in further release of Ca^{2+} from the intracellular sarcoplasmic reticulum store (known as Ca^{2+}-induced Ca^{2+} release), which binds to troponin C to promote myofilament contraction. PKA also phosphorylates myofilament proteins to achieve a net increase in their Ca^{2+} sensitivity, which further enhances contractile force during β-adrenergic stimulation. PKA activation in blood vessels also contributes to their vasodilation which enhances the blood supply to the cardiac muscle during the increased energy demand.

PKA is redox-regulated, independently of the classical cAMP mechanism, by a mechanism involving interprotein disulfide bond formation in the regulatory R1α subunits (Fig. 5) (8). The R1α regulatory subunit of PKA was identified as being redox sensitive following a proteomic screen, using diagonal polyacylamide gel electrophoresis, for proteins that form interprotein disulfide complexes. The identification of two disulfides that link the R1α regulatory subunits of PKA (PKARI) was first reported by Zick and Taylor (70), with Cys 16 bonding to Cys 37, forming an anti-parallel dimer containing two double disulfide bonds. These were considered constitutive structural disulfides (38); however these disulfides are not required for dimerization of the 1α regulatory subunits as they are held together by an amphipathic leucine zipper. These disulfides were hypothesized to serve as oxidant sensors, forming the disulfides only during pro-oxidizing conditions. Indeed PKAR1α displayed a H_2O_2 concentration-dependent increase in disulfide dimer formation in the absence of reducing agent, which was fully returned to the monomeric mass when analyzed with reducing agent present. PKAR1α disulfide bond formation was associated with elevated PKA catalytic activity, which was attenuated by the PKA inhibitor H89, although this antagonist has selectivity issues. Substrate phosphorylation following H_2O_2 treatment was also independent of cAMP elevation. Subcellular fractionation studies showed that disulfide-oxidized kinase translocated from the cytosol to the myofilament/nuclear fraction and to the membrane. This translocation and increased activity of PKA following oxidation may be explained by increased affinity for its binding partners known as A-kinase anchoring proteins (AKAPs). The inter-protein disulfides between the R1α subunits are located within the AKAP

FIG. 6. Classical cGMP and oxidative disulfide mechanism for activating PKG1α. The binding of cGMP to PKG1α results in a conformational change in structure that exposes the catalytic site, leading to increased substrate phosphorylation. Alternatively, the formation of intramolecular disulfide between two monomers of PKG1α leads to increased catalytic activity independently of cGMP by increasing the enzyme affinity for substrate.

interaction domain and precisely flank the site of AKAP-R1 binding. Recent studies comparing disulfide wild-type R1α binding to D-AKAP with mutants that cannot form a disulfide showed Cys16Ala and Cys37Ala mutations reduced the interaction 3- or 16-fold, respectively (51). PKA interaction with its AKAPs potentially goes beyond the simple concept that this brings the enzyme closer to its substrates, as the presence of substrate itself can increase the dissociation of the catalytic and regulatory subunits (61). This substrate-dependent effect appears to be specific to type 1α form of PKA and may help explain how oxidation of this kinase leads to an increase in the phosphorylation of its substrates without an elevation in cAMP. PKAR1α disulfide oxidation is also induced by CysNO (12), a compound that induced vasodilation in isolated aortic vessels independently of cAMP. PKAR1α disulfide oxidation may therefore have a role in vascular relaxation, especially considering other thiol-oxidizing molecules such as H₂O₂ efficiently induce vasodilation.

In addition to the finding that PKA1α may be activated by regulatory subunit disulfide formation is a report that oxidation of the catalytic subunit can lead to kinase inactivation. The formation of an intramolecular disulfide bond between Cys- 199 and -343 of the catalytic subunit or its glutathionylation at Cys-199 inactivated the kinase (29). This discrepancy could be due to the experimental models examined, including the type and concentration of oxidant. The R2 and C2 subunits of PKA have also been shown to disulfide dimerize in the presence of oxidants (20). Subsequent studies showed this disulfide inactivates the kinase (17).

cGMP-dependent protein kinase

The regulation of vasotone is crucial for maintaining blood pressure and tissue perfusion with its dysregulation increasing the risk of heart attacks, peripheral artery disease, heart failure, aortic aneurysms, kidney failure, and stroke (24, 40). A major regulator of vasodilation within the vasculature is the kinase cyclic guanosine monophosphate (cGMP)-dependent protein kinase, also commonly called protein kinase G (PKG) (58).

PKG is expressed as two isoforms termed type 1 (PKG1) and type 2 (PKG2). Type 1 is predominately expressed in the cardiovascular system and has two splice variants, PKG1α and PKG1β, which differ only in the first N-terminal ∼100 amino acids. PKG is a parallel-aligned homodimer due to a leucine zipper interaction within the regulatory N-terminal region between each subunit. Unlike PKA, the catalytic and regulatory domains of PKG are fused together as a single subunit. Two molecules of cGMP bind to each subunit of PKG causing a conformational change in the protein structure exposing the catalytic site of the enzyme to induce activation. The proposed structure of inactive PKG1α is a folded conformation, with the catalytic C-terminus being inactive through an interaction with the pseudosubstrate N-terminal autoinhibitory domain (Fig. 6) (1, 10, 44). Hydrogen/deuterium exchange analysis has also identified changes in the structural interfaces of PKG1α that occur during cGMP activation (1), showing the autoinhibitory domain, the hinge region, and the substrate interaction domain in PKG1α becoming more solvent accessible when cGMP binds. This was accompanied by a loss in solvent accessibility of the cGMP binding sites, suggesting a dramatic change in the structure of PKG1α in which the N-terminal and catalytic domain move apart during classical allosteric activation. Gel filtration studies have also shown that when cGMP binds PKG1α that the kinase elongates, consistent with a structural change that would expose the catalytic site (48).

PKG1α is also sensitive to oxidation through the formation of an intermolecular disulfide bond (Fig. 6) (13). Isolated rat hearts perfused with H₂O₂ showed a dose-dependent increase

in the formation of a disulfide dimer complex. A disulfide between the two monomers of PKG1α was first reported in 1980, demonstrating a bond between Cys-42 on each chain (41), but this was considered a structurally constitutive modification. It is clear that under basal conditions PKG1α does not contain a disulfide, but when cellular oxidant levels are increased, the disulfide readily forms. Isolated rat hearts exposed to H_2O_2 vasodilated to a similar extent to that induced by an NO donor. Follow-up studies measuring tension in isolated rat aortic rings showed H_2O_2 increased vasodilation in a PKG-dependent manner even when guanylate cyclase activity and cGMP production was blocked, consistent with cGMP-independent activation. *In vitro* kinase activity assays confirmed disulfide oxidation does indeed increase PKG1α activity independently of cGMP. The kinetics of disulfide activation was measured by Michaelis Menten analysis, showing that disulfide formation increases the affinity of PKG1α for its substrates. This differed from the classical mechanism involving allosteric activation by cGMP, which enhanced the V_{max} of the kinase. The enhanced affinity for substrates after oxidation underlies the kinases translocation to subcellular compartments containing targets for phosphorylation.

The transnitrosylating nitrosothiol CysNO, also efficiently disulfide-activated PKG1α (12), contributing to the associated vasodilation of aortic rings, which was significantly guanylate cyclase insensitive. This novel mode of oxidatively activating PKG1α represents a potential mechanism underlying endothelial derived hyperpolarizing factor (EDHF)-induced vasodilation. Indeed, a role for PKG1α oxidation by H_2O_2 as a mediator of the EDHF response has been substantiated using Cys42Ser PKG1α knock-in (KI) mice. These KI mice cannot undergo disulfide-induced activation due to single atom substitution of the redox sensitive sulfur for an oxygen (47). The KI mice have elevated resting blood pressure, consistent with basal PKG1α disulfide oxidation being an important mediator of physiological vascular tone. In addition, resistance vessels from KI mice had a blunted EDHF response to acetylcholine. Oxidant-induced disulfide activation of PKG1α has also been demonstrated in human coronary arterioles (67). Flow and H_2O_2 induced dilation in these vessels was shown to be largely dependent on stimulation of BKca channels that could be attenuated by a PKG inhibitor but not a guanylate cyclase inhibitor. Overall, there is now robust evidence that PKG1α oxidation occurs physiologically to regulate vasotone, and these events occur in human tissues.

Conclusion

The formation and ability of H_2O_2 to modulate intracellular signaling is dynamically regulated by the relative activity of oxidant generating enzymes, peroxidases, and reducing proteins. Changes in H_2O_2 bioavailability modulates physiological signaling by altering the oxidation status of select target proteins. Its targets in the cardiovascular system include the kinases PKA, PKG, and CAMKII, which upon oxidation undergo a functional change, providing a mechanism by which oxidant generation can couple to phospho-signaling. The oxidation of each of these kinases plays an important role in regulating normal physiological signaling. However, under conditions of oxidative stress, where oxidant formation becomes dysregulated, the oxidation of these kinases may contribute to disease progression due to loss in normal cellular phospho-regulation. Therefore, the use of antioxidants or drugs that can prevent oxidation of select redox-sensitive targets may prove beneficial under certain disease conditions.

Acknowledgments

Author Disclosure Statement

No competing financial interests exist.

References

1. Alverdi V, Mazon H, Versluis C, Hemrika W, Esposito G, van den Heuvel R, Scholten A, and Heck AJ. cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. *J Mol Biol* 375: 1380–1393, 2008.

2. Antunes F and Cadenas E. Estimation of H2O2 gradients across biomembranes. *FEBS Lett* 475: 121–126, 2000.

3. Baldwin SR, Simon RH, Grum CM, Ketai LH, Boxer LA, and Devall LJ. Oxidant activity in expired breath of patients with adult respiratory distress syndrome. *Lancet* 1: 11–14, 1986.

4. Benovic JL, Bouvier M, Caron MG, and Lefkowitz RJ. Regulation of adenylyl cyclase-coupled beta-adrenergic receptors. *Annu Rev Cell Biol* 4: 405–428, 1988.

5. Biteau B, Labarre J, and Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by *S. cerevisiae* sulphiredoxin. *Nature* 425: 980–984, 2003.

6. This reference has been deleted.

7. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* 297: 842–857, 2007.

8. Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schroder E, Wait R, Begum S, Kentish JC, and Eaton P. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. *J Biol Chem* 281: 21827–21836, 2006.

9. Brennan JP, Wait R, Begum S, Bell JR, Dunn MJ, and Eaton P. Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. *J Biol Chem* 279: 41352–41360, 2004.

10. Browning DD, Mc Shane M, Marty C, and Ye RD. Functional analysis of type 1alpha cGMP-dependent protein kinase using green fluorescent fusion proteins. *J Biol Chem* 276: 13039–13048, 2001.

11. Budanov AV, Sablina AA, Feinstein E, Koonin EV, and Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. *Science* 304: 596–600, 2004.

12. Burgoyne JR and Eaton P. Transnitrosylating nitric oxide species directly activate type I protein kinase A, providing a novel adenylate cyclase-independent cross-talk to beta-adrenergic-like signaling. *J Biol Chem* 284: 29260–29268, 2009.

13. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schroder E, Browning DD, and Eaton P. Cysteine redox sensor in PKGIa enables oxidant-induced activation. *Science* 317: 1393–1397, 2007.

14. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, and Shah AM. NADPH oxidases in

cardiovascular health and disease. *Antioxid Redox Signal* 8: 691–728, 2006.

15. Charles RL, Burgoyne JR, Mayr M, Weldon SM, Hubner N, Dong H, Morisseau C, Hammock BD, Landar A, and Eaton P. Redox regulation of soluble epoxide hydrolase by 15-deoxy-delta-prostaglandin J(2) controls coronary hypoxic vasodilation. *Circ Res* 108: 324–334, 2011.

16. Cohen MS, Hadjivassiliou H, and Taunton J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. *Nat Chem Biol* 3: 156–160, 2007.

17. de Pina MZ, Vazquez-Meza H, Pardo JP, Rendon JL, Villalobos-Molina R, Riveros-Rosas H, and Pina E. Signaling the signal, cyclic AMP-dependent protein kinase inhibition by insulin-formed H2O2 and reactivation by thioredoxin. *J Biol Chem* 283: 12373–12386, 2008.

18. Dick DJ, Harrison FG, Okane PD, and Halliwell OT. Preconditioning of mechanically induced premature ventricular beats in the isolated rabbit heart. *J Physiol-London* 459: P509, 1993.

19. Droge W. Free radicals in the physiological control of cell function. *Physiol Rev* 82: 47–95, 2002.

20. First EA and Taylor SS. Induced interchain disulfide bonding in cAMP-dependent protein kinase II. *J Biol Chem* 259: 4011–4014, 1984.

21. Forman HJ. Use and abuse of exogenous H2O2 in studies of signal transduction. *Free Radic Biol Med* 42: 926–932, 2007.

22. Gitler C, Zarmi B, and Kalef E. General method to identify and enrich vicinal thiol proteins present in intact cells in the oxidized, disulfide state. *Anal Biochem* 252: 48–55, 1997.

23. He BJ, Joiner ML, Singh MV, Luczak ED, Swaminathan PD, Koval OM, Kutschke W, Allamargot C, Yang J, Guan X, Zimmerman K, Grumbach IM, Weiss RM, Spitz DR, Sigmund CD, Blankesteijn WM, Heymans S, Mohler PJ, and Anderson ME. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. *Nat Med* 17: 1610–1618, 2011.

24. Hering D, Esler MD, Krum H, Mahfoud F, Bohm M, Sobotka PA, and Schlaich MP. Recent advances in the treatment of hypertension. *Expert Rev Cardiovasc Ther* 9: 729–744, 2011.

25. Hess DT, Matsumoto A, Kim SO, Marshall HE, and Stamler JS. Protein S-nitrosylation: Purview and parameters. *Nat Rev Mol Cell Biol* 6: 150–166, 2005.

26. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, and Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nat Med* 5: 1135–1142, 1999.

27. Horoz M, Bolukbas C, Bolukbas FF, Aslan M, Koylu AO, Selek S, and Erel O. Oxidative stress in hepatitis C infected end-stage renal disease subjects. *BMC Infect Dis* 6: 114, 2006.

28. Hudmon A and Schulman H. Structure-function of the multifunctional Ca2 + /calmodulin-dependent protein kinase II. *Biochem J* 364: 593–611, 2002.

29. Humphries KM, Juliano C, and Taylor SS. Regulation of cAMP-dependent protein kinase activity by glutathionylation. *J Biol Chem* 277: 43505–43511, 2002.

30. Hyslop PA, Zhang Z, Pearson DV, and Phebus LA. Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: Correlation with the cytotoxic potential of H2O2 *in vitro*. *Brain Res* 671: 181–186, 1995.

31. Jonsson TJ, Johnson LC, and Lowther WT. Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. *Nature* 451: 98–101, 2008.

32. Kamata H, Honda S, Maeda S, Chang L, Hirata H, and Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. *Cell* 120: 649–661, 2005.

33. Kim C, Cheng CY, Saldanha SA, and Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. *Cell* 130: 1032–1043, 2007.

34. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, and Loukides S. Oxidative stress in expired breath condensate of patients with COPD. *Chest* 124: 1373–1380, 2003.

35. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, and Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: Role of heredity, gender, and ethnicity. *Hypertension* 36: 878–884, 2000.

36. Lacy F, O'Connor DT, and Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. *J Hypertens* 16: 291–303, 1998.

37. Leitch JM, Yick PJ, and Culotta VC. The right to choose: Multiple pathways for activating copper,zinc superoxide dismutase. *J Biol Chem* 284: 24679–24683, 2009.

38. Leon DA, Herberg FW, Banky P, and Taylor SS. A stable alpha-helical domain at the N terminus of the RIalpha subunits of cAMP-dependent protein kinase is a novel dimerization/docking motif. *J Biol Chem* 272: 28431–28437, 1997.

39. Maller C, Schroder E, and Eaton P. Glyceraldehyde 3-phosphate dehydrogenase is unlikely to mediate hydrogen peroxide signaling: Studies with a novel anti-dimedone sulfenic acid antibody. *Antioxid Redox Signal* 14: 49–60, 2011.

40. Mathew R. Pulmonary hypertension: Current therapy and future prospects. *Cardiovasc Hematol Agents Med Chem* 9: 165–182, 2011.

41. Monken CE and Gill GN. Structural analysis of cGMP-dependent protein kinase using limited proteolysis. *J Biol Chem* 255: 7067–7070, 1980.

42. Nemoto S and Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. *Science* 295: 2450–2452, 2002.

43. Ogura Y and Yamazaki I. Steady-state kinetics of the catalase reaction in the presence of cyanide. *J Biochem* 94: 403–408, 1983.

44. Osborne BW, Wu J, McFarland CJ, Nickl CK, Sankaran B, Casteel DE, Woods VL, Jr., Kornev AP, Taylor SS, and Dostmann WR. Crystal structure of cGMP-dependent protein kinase reveals novel site of interchain communication. *Structure* 19: 1317–1327, 2011.

45. Palomeque J, Rueda OV, Sapia L, Valverde CA, Salas M, Petroff MV, and Mattiazzi A. Angiotensin II-induced oxidative stress resets the Ca2+ dependence of Ca2+-calmodulin protein kinase II and promotes a death pathway conserved across different species. *Circ Res* 105: 1204–1212, 2009.

46. Peskin AV, Low FM, Paton LN, Maghzal GJ, Hampton MB, and Winterbourn CC. The high reactivity of peroxiredoxin 2 with H(2)O(2) is not reflected in its reaction with other oxidants and thiol reagents. *J Biol Chem* 282: 11885–11892, 2007.

47. Prysyazhna O, Rudyk O, and Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. *Nat Med* 18: 286–290, 2012.

48. Richie-Jannetta R, Busch JL, Higgins KA, Corbin JD, and Francis SH. Isolated regulatory domains of cGMP-dependent

protein kinase Ialpha and Ibeta retain dimerization and native cGMP-binding properties and undergo isoform-specific conformational changes. *J Biol Chem* 281: 6977–6984, 2006.

49. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. *EMBO J* 17: 2596–2606, 1998.

50. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. *Nature* 423: 769–773, 2003.

51. Sarma GN, Kinderman FS, Kim C, von Daake S, Chen L, Wang BC, and Taylor SS. Structure of D-AKAP2:PKA RI complex: Insights into AKAP specificity and selectivity. *Structure* 18: 155–166, 2010.

52. Schröder E, Brennan JP, and Eaton P. Cardiac peroxiredoxins undergo complex modifications during cardiac oxidant stress. *Am J Physiol (Heart)* 295: 425–433, 2008.

53. Schroder E and Eaton P. Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: Issues and considerations. *Curr Opin Pharmacol* 8: 153–159, 2008.

54. Skelding KA and Rostas JA. Regulation of CaMKII *in vivo*: The importance of targeting and the intracellular microenvironment. *Neurochem Res* 34: 1792–1804, 2009.

55. Song YH, Cho H, Ryu SY, Yoon JY, Park SH, Noh CI, Lee SH, and Ho WK. L-type Ca(2+) channel facilitation mediated by H(2)O(2)-induced activation of CaMKII in rat ventricular myocytes. *J Mol Cell Cardiol* 48: 773–780, 2010.

56. Song YH, Choi E, Park SH, Lee SH, Cho H, Ho WK, and Ryu SY. Sustained CaMKII activity mediates transient oxidative stress-induced long-term facilitation of L-type Ca(2+) current in cardiomyocytes. *Free Radic Biol Med* 51: 1708–1716, 2011.

57. Suematsu M, Schmid-Schonbein GW, Chavez-Chavez RH, Yee TT, Tamatani T, Miyasaka M, Delano FA, and Zweifach BW. *In vivo* visualization of oxidative changes in microvessels during neutrophil activation. *Am J Physiol* 264: H881–891, 1993.

58. Surks HK. cGMP-dependent protein kinase I and smooth muscle relaxation: A tale of two isoforms. *Circ Res* 101: 1078–1080, 2007.

59. Sznajder JI, Fraiman A, Hall JB, Sanders W, Schmidt G, Crawford G, Nahum A, Factor P, and Wood LD. Increased hydrogen peroxide in the expired breath of patients with acute hypoxemic respiratory failure. *Chest* 96: 606–612, 1989.

60. Test ST and Weiss SJ. Quantitative and temporal characterization of the extracellular H2O2 pool generated by human neutrophils. *J Biol Chem* 259: 399–405, 1984.

61. Vigil D, Blumenthal DK, Taylor SS, and Trewhella J. The conformationally dynamic C helix of the RIalpha subunit of protein kinase A mediates isoform-specific domain reorganization upon C subunit binding. *J Biol Chem* 280: 35521–35527, 2005.

62. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. *Nat Chem Biol* 4: 278–286, 2008.

63. Woo HA, Bae SH, Park S, and Rhee SG. Sestrin 2 is not a reductase for cysteine sulfinic acid of peroxiredoxins. *Antioxid Redox Signal* 11: 739–745, 2009.

64. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, and Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. *Science* 300: 653–656, 2003.

65. Wood ZA, Poole LB, and Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. *Science* 300: 650–653, 2003.

66. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, and Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. *J Biol Chem* 277: 38029–38036, 2002.

67. Zhang DX, Borbouse L, Gebremedhin D, Mendoza SA, Zinkevich NS, Li R, and Gutterman DD. H2O2-induced dilation in human coronary arterioles: Role of protein kinase G dimerization and large-conductance Ca2+-activated K+ channel activation. *Circ Res* 110: 471–480, 2012.

68. Zhang J, Yang PL, and Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer* 9: 28–39, 2009.

69. Zhu W, Woo AY, Yang D, Cheng H, Crow MT, and Xiao RP. Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. *J Biol Chem* 282: 10833–10839, 2007.

70. Zick SK and Taylor SS. Interchain disulfide bonding in the regulatory subunit of cAMP-dependent protein kinase I. *J Biol Chem* 257: 2287–2293, 1982.

Address correspondence to:
Dr. Philip Eaton
Cardiovascular Division
King's College London
The Rayne Institute, 4th Floor, Lambeth Wing
St. Thomas' Hospital
London SE1 7EH
United Kingdom

E-mail: philip.eaton@kcl.ac.uk

Abbreviations Used

AKAPs = A-kinase anchoring proteins
AKS-1 = apoptosis signal-regulating kinase-1
ATP = adenosine-5′-triphosphate
CaMKII = Ca^{2+}/calmodulin-dependent kinase II
cAMP = cyclic adenosine 3′,5′-monophosphate
cGMP = cyclic guanosine monophosphate
EDHF = endothelial derived hyperpolarizing factors
Grx = glutaredoxin
MsrA = methionine sulfoxide reductase A
NOX = NADPH oxidase
PKA = protein kinase A
PKARI = R1α regulatory subunits of PKA
PKG = protein kinase G
PSH = protein thiols
PTP1B = protein tyrosine phosphatase 1B
ROS = reactive oxidant species
Trx = thioredoxin